Home Visit app to optimize virtual clinical trials

07 May 2020

Cmed Technology announced today the encapsia Home Visit app is now available to capture and manage clinical trial data from patients at home or in the community. The app works seamlessly with all the other encapsia apps, including web EDC (Entry app) and direct data capture (esource app) to provide tremendous flexibility in the choice of data capture methods both before and during a study. This helps maintain patient participation and clinical data flow which is particularly compelling to minimize disruption during the COVID-19 pandemic as well as in the new landscape for clinical trials that is expected to follow.

Support for Virtual Clinical Trials from Cmed

30 Apr 2020

The dramatic coronavirus (COVID-19) pandemic has disrupted all aspects of daily life including clinical trials. Medical staff limitations and reorganizations, travel bans and access restrictions to medical facilities have challenged sponsors and sites’ current clinical trial processes.
The coronavirus outbreak has effectively forced a change in patient care and clinical trials. To continue bringing new therapies to market and support patients, sites and sponsors have accelerated the adoption of new technologies into decentralized trials or hybrid trials.

A message for our clients, investigator sites and industry partners

06 Apr 2020

The global COVID-19 crisis has fundamentally impacted the way we live our lives as well as the operation of the entire drug development community. During the early stages of the pandemic the Cmed leadership team has implemented a number of measures to ensure the safety of our employees, clients and partners, as well as ensuring the continued delivery of our CRO services and our encapsia clinical data system. Our goal has been to minimise the impact of COVID-19 on our business, our clients, investigator sites and patients.

A message for our clients, investigator sites and industry partners

Written by David M Connelly, Chief Executive Officer

The global COVID-19 crisis has fundamentally impacted the way we live our lives as well as the operation of the entire drug development community. During the early stages of the pandemic the Cmed leadership team has implemented a number of measures to ensure the safety of our employees, clients and partners, as well as ensuring the continued delivery of our CRO services and our encapsia clinical data system. Our goal has been to minimise the impact of COVID-19 on our business, our clients, investigator sites and patients. For your information:

Cmed staff are working remotely in all countries, with all systems working smoothly

support or rescue ongoing studies that may be in difficulty, especially for example where data flow has become interrupted

support Extended Access Programs through rapid database build and start-up, flexibility and ease of use

Accelerate the release of the encapsia Home Visit app to support on and offline capture of clinical trial data from a patients’ home.

To sponsors leading the fight in the treatment of COVID-19

Cmed will provide encapsia and associated services for COVID-19 studies on a Not for Profit basis. This is a sincere and genuine offer.

Cmed management is fully committed to support the fight against COVID-19 and truly believes we can facilitate the capture and management of data for these types of studies more efficiently and quickly than other clinical data systems. COVID-19 studies need to be started rapidly, with high quality data from the outset, support CRAs who may not be able to visit the sites, as well as facilitate immediate decision making with immediate and real-time access to the study data 24x7.

We expect there will be many more significant challenges ahead and we are committed to overcome them through resourceful, innovative and flexible approaches and thinking. We also want to express our continuing gratitude to our colleagues and friends in the industry. Despite these difficult times, which drive a bleak short-term outlook for the world, we are confident our industry of clinical research can provide the solutions for a brighter, better future.

With best wishes and good health on behalf of the Cmed Leadership Team